Quaking isoforms cooperate to promote the mesenchymal phenotype.


Journal

Molecular biology of the cell
ISSN: 1939-4586
Titre abrégé: Mol Biol Cell
Pays: United States
ID NLM: 9201390

Informations de publication

Date de publication:
29 Nov 2023
Historique:
medline: 29 11 2023
pubmed: 29 11 2023
entrez: 29 11 2023
Statut: aheadofprint

Résumé

The RNA-binding protein Quaking (QKI) has widespread effects on mRNA regulation including alternative splicing, stability, translation, and localization of target mRNAs. Recently, QKI was found to be induced during epithelial-mesenchymal transition (EMT), where it promotes a mesenchymal alternative splicing signature that contributes to the mesenchymal phenotype. QKI is itself alternatively spliced to produce three major isoforms, QKI-5, QKI-6, and QKI-7. While QKI-5 is primarily localized to the nucleus where it controls mesenchymal splicing during EMT, the functions of the two predominantly cytoplasmic isoforms, QKI-6, and QKI-7, in this context remain uncharacterized. Here we employed CRISPR-mediated depletion of QKI in a human mammary epithelial cell model of EMT and studied the effects of expressing the QKI isoforms in isolation and in combination. QKI-5 was required to induce mesenchymal morphology, while combined expression of QKI-5 with either QKI-6 or QKI-7 further enhanced mesenchymal morphology and cell migration. In addition, we found that QKI-6 and QKI-7 can partially localize to the nucleus and contribute to alternative splicing of QKI target genes. These findings indicate that the QKI isoforms function in a dynamic and cooperative manner to promote the mesenchymal phenotype.

Identifiants

pubmed: 38019605
doi: 10.1091/mbc.E23-08-0316
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

mbcE23080316

Auteurs

Daniel P Neumann (DP)

Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, 5000, Australia.

Caroline A Phillips (CA)

Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, 5000, Australia.

Rachael Lumb (R)

Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, 5000, Australia.

Helen M Palethorpe (HM)

Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, 5000, Australia.

Yesha Ramani (Y)

Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, 5000, Australia.

Brett G Hollier (BG)

Australian Prostate Cancer Research Centre - Queensland, Centre for Genomics and Personalised Health, Faculty of Health, School of Biomedical Sciences, Queensland University of Technology, Translational Research Institute, Brisbane, QLD, 4102, Australia.

Luke A Selth (LA)

Flinders Health and Medical Research Institute and Freemasons Centre for Male Health and Wellbeing, Flinders University, Bedford Park, SA, 5042, Australia.
Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA 5000, Australia.

Cameron P Bracken (CP)

Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, 5000, Australia.
Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA 5000, Australia.
School of Biological Sciences, Faculty of Sciences, Engineering and Technology, The University of Adelaide, Adelaide, SA 5000, Adelaide.

Gregory J Goodall (GJ)

Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, 5000, Australia.
Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA 5000, Australia.
School of Biological Sciences, Faculty of Sciences, Engineering and Technology, The University of Adelaide, Adelaide, SA 5000, Adelaide.

Philip A Gregory (PA)

Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, 5000, Australia.
Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA 5000, Australia.

Classifications MeSH